Bilcare Limited (526853) Fair Value & Analysis
Other · IN · Market cap ₹1.1B
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price −6.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹51.94 – ₹112.45 · fair‑value band ₹9.31 – ₹15.52 · the ₹60.46 price screens above the ₹12.42 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bilcare Limited (526853) currently trades at ₹60.46, while our model-based Fair Value estimate is ₹12.42 — implying the stock looks roughly 79.5% overvalued today. We read business quality at 49/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Bilcare Limited generated revenue of ₹7.2B at a net margin of 13.6%. Revenue declined 76.9% year over year. Net debt stands at ₹6.0B. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Bilcare Limited provides pharmaceutical packaging research solutions and global clinical services in India and internationally. The company offers various specialty polymer films and aluminum foils primarily used for packaging solid dosage pharmaceutical products; and other packaging films solutions for applications in ID card, specialty film, and food packaging industries. It also provides clinical trial materials supplies and project management services; and nonClonableID, an anti-counterfeiting, security, and brand protection solution for various industry sectors. The company serves pharmaceutical and biotechnology industries. Bilcare Limited was incorporated in 1987 and is based in Pune, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Bilcare Limited reported revenue of ₹7.3B in FY2026 versus ₹8.4B in FY2022, a compound −3.5%/yr. Reported net income was ₹17.2M in FY2026.
Is 526853 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Bilcare Limited (526853) undervalued?
What is the fair value of 526853?
What is the quality score of 526853?
What is the revenue of Bilcare Limited (526853)?
What is the net profit margin of 526853?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.